Citations (53)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Defeng Qing, Yuying Wu, Xu Liu, Hailan Jiang, Chaohua Zhu, Pei Liu, Junming Dang, Xianglong Li, Zhaohong Chen, Xianfeng Long, Qiang Pang, Luxing Peng, Shan Deng, Junzhao Gu, Renfeng Zhao, Changyi Chen & Heming Lu. (2020) Long-Term Results of Concurrent Chemoradiotherapy Combined with Anti-EGFR Monoclonal Antibody Prior to Surgery in Locally Advanced Cervical Cancer: A Single-Institute Prospective Study. Cancer Management and Research 12, pages 12309-12317.
Read now
Read now
Xianghe Liu, Yahui Zhao, Weina Zhang, Yang Gao, Miaomiao Huo, Mei Liu, Zefen Xiao, Shufang Liang, Ningzhi Xu & Hongxia Zhu. (2018) Inhibition of survivin enhances radiosensitivity of esophageal cancer cells by switching radiation-induced senescence to apoptosis. OncoTargets and Therapy 11, pages 3087-3100.
Read now
Read now
Heming Lu, Yuying Wu, Xu Liu, Hailan Jiang, Qiang Pang, Luxing Peng, Jinjian Cheng, Shan Deng, Junzhao Gu, Renfeng Zhao, Xiaoxia Hu, Changyi Chen & Jinming Yu. (2018) A prospective study on neoadjuvant chemoradiotherapy plus anti-EGFR monoclonal antibody followed by surgery for locally advanced cervical cancer. OncoTargets and Therapy 11, pages 3785-3792.
Read now
Read now
Assuntina G Sacco & Francis P Worden. (2016) Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors. OncoTargets and Therapy 9, pages 1927-1943.
Read now
Read now
Nicholas P. Campbell, Thomas A. Hensing, Mihir K. Bhayani, Arif Y. Shaikh & Bruce E. Brockstein. (2016) Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck. Expert Review of Anticancer Therapy 16:8, pages 847-858.
Read now
Read now
Lucely Cetina, Tania Crombet, Roberto Jiménez-Lima, Sergio Zapata, Mayra Ramos, Sandra Avila, Jaime Coronel, Eduardo Charco, Rafael Bojalil, Horacio Astudillo, Blanca Bazán & Alfonso Dueñas-González. (2015) A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer. Cancer Biology & Therapy 16:5, pages 684-689.
Read now
Read now
Yihui Wen & Jennifer R Grandis. (2015) Emerging drugs for head and neck cancer. Expert Opinion on Emerging Drugs 20:2, pages 313-329.
Read now
Read now
Arlhee Diaz-Miqueli & Giselle Saurez Martinez. (2013) Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities. OncoTargets and Therapy 6, pages 931-942.
Read now
Read now
Articles from other publishers (45)
Dev Amin, Tony RichaMehri MollaeeTingting ZhanPatrick Tassone, Jennifer JohnsonAdam LuginbuhlDavid CognettiUbaldo Martinez‐OutschoornRobert StappCharalambos SolomidesUlrich RodeckJoseph Curry. (2019)
Metformin Effects on FOXP3
+
and CD8
+
T Cell Infiltrates of Head and Neck Squamous Cell Carcinoma
. The Laryngoscope 130:9.
Crossref
Crossref
Mengping Zhang, He Huang, Xueying Li, Ying Huang, Chunyan Chen, Xiaojie Fang, Zhao Wang, Chengcheng Guo, Sioteng Lam, Xiaohong Fu, Huangming Hong, Ying Tian, Taixiang Lu & Tongyu Lin. (2020) Long-Term Survival of Patients With Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen. Frontiers in Oncology 10.
Crossref
Crossref
Tania Crombet Ramos, Braulio Mestre Fernández, Zaima Mazorra Herrera & Normando E. Iznaga Escobar. (2020) Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck. Frontiers in Oncology 10.
Crossref
Crossref
Carmen Viada, Aliz M. Vega, Mayte Robaina, Aliuska Frías, Mabel Álvarez, Yanela Santiesteban, Yuliannis Santiesteban, Lázara García, Braulio Mestre, Marta xxx Osorio, Leslie Pérez, Amparo Macias, Tania Crombet & Mayra Ramos. (2020) Evaluation of Nimotuzumab for the treatment of head and neck cancer: Meta-analysis of controlled trials. Bionatura 5:1, pages 1056-1062.
Crossref
Crossref
Sai-xi Bai, Ruo-rong Zhang, Wang-hua Chen, Hong-min Dong, Gang Wang, Xiao-kai Li & Wenling Wang. (2020) Clinical efficacy and safety of nimotuzumab plus chemotherapy in patients with advanced colorectal cancer: a retrospective analysis. Journal of International Medical Research 48:1, pages 030006051989585.
Crossref
Crossref
S. Kareemaghay & M. Tavassoli. (2019) Clinical immunotherapeutic approaches for the treatment of head and neck cancer. International Journal of Oral and Maxillofacial Surgery 48:4, pages 419-436.
Crossref
Crossref
Jiancheng Li, Linghua Wang, Zidan Qiu & Ying Su. (2019) Time profile of nimotuzumab for enhancing radiosensitivity of the Eca109 cell line. Oncology Letters.
Crossref
Crossref
Nuzhat Husain & Azfar Neyaz. 2019. Molecular Diagnostics in Cancer Patients. Molecular Diagnostics in Cancer Patients
165
185
.
Leslie Pérez Ruiz, Manuel Miguel Collazo Herrera, Normando Iznaga Escobar, Anai García Fariñas & Osvaldo Ulises Garay. (2018) Eficiencia del nimotuzumab en la atención a pacientes con cáncer de cabeza y cuello en Cuba. PharmacoEconomics Spanish Research Articles 15:1-4, pages 13-23.
Crossref
Crossref
Zaima Mazorra, Lisset Chao, Anabel Lavastida, Belinda Sanchez, Mayra Ramos, Normando Iznaga & Tania Crombet. (2018) Nimotuzumab: beyond the EGFR signaling cascade inhibition. Seminars in Oncology 45:1-2, pages 18-26.
Crossref
Crossref
Yiming Li, Xing Liu, Kaibin Xu, Zenghui Qian, Kai Wang, Xing Fan, Shaowu Li, Yinyan Wang & Tao Jiang. (2017) MRI features can predict EGFR expression in lower grade gliomas: A voxel-based radiomic analysis. European Radiology 28:1, pages 356-362.
Crossref
Crossref
Peng Song, Jing Yang, Xiaomei Li, Haili Huang, Xueguang Guo, Gang Zhou, Xian Xu, Yi Cai, Min Zhu, Peng Wang, Shu Zhao & Dong Zhang. (2017) Hepatocellular carcinoma treated with anti-epidermal growth factor receptor antibody nimotuzumab. Medicine 96:39, pages e8122.
Crossref
Crossref
Mary Jue Xu, Daniel E. Johnson & Jennifer R. Grandis. (2017) EGFR-targeted therapies in the post-genomic era. Cancer and Metastasis Reviews 36:3, pages 463-473.
Crossref
Crossref
Zaima Mazorra, Anabel Lavastida, Fernando Concha-Benavente, Anet Valdés, Raghvendra M. Srivastava, Tatiana M. García-Bates, Esperanza Hechavarría, Zuyen González, Amnely González, Martha Lugiollo, Iván Cuevas, Carlos Frómeta, Braulio F. Mestre, Maria C. Barroso, Tania Crombet & Robert L. Ferris. (2017) Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients. Frontiers in Pharmacology 8.
Crossref
Crossref
Philippe E. Spiess, Jasreman Dhillon, Adam S. Baumgarten, Peter A. Johnstone & Anna R. Giuliano. (2016) Pathophysiological basis of human papillomavirus in penile cancer: Key to prevention and delivery of more effective therapies. CA: A Cancer Journal for Clinicians 66:6, pages 481-495.
Crossref
Crossref
Paolo Bossi, Carlo Resteghini, Nicholas Paielli, Lisa Licitra, Silvana Pilotti & Federica Perrone. (2016) Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma. Oncotarget 7:45, pages 74362-74379.
Crossref
Crossref
Chloé Rancoule, Alexis Vallard, Sophie Espenel, Jean-Baptiste Guy, Yaoxiong Xia, Anis El Meddeb Hamrouni, Claire Rodriguez-Lafrasse, Cyrus Chargari, Eric Deutsch & Nicolas Magné. (2016) Immunotherapy in head and neck cancer: Harnessing profit on a system disruption. Oral Oncology 62, pages 153-162.
Crossref
Crossref
Rony Benson, Supriya Mallick, P.K. Julka & G.K. Rath. (2016) Anti EGFR therapy in the treatment of non-metastatic head and neck squamous cell carcinoma: The current evidence. Journal of the Egyptian National Cancer Institute 28:3, pages 141-148.
Crossref
Crossref
Matthew Zibelman & Ranee Mehra. (2016) Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck. American Journal of Clinical Oncology 39:4, pages 396-406.
Crossref
Crossref
Rebecca C. Hoesli & Jeffrey S. Moyer. (2016) Immunotherapy for Head and Neck Squamous Cell Carcinoma. Current Oral Health Reports 3:2, pages 74-81.
Crossref
Crossref
Shuping Xu, Mayra Ramos-Suzarte, Xianhong Bai & Binghe Xu. (2016) Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience. Oncotarget 7:22, pages 33391-33407.
Crossref
Crossref
Han Na Kang, Se-Ho Kim, Mi Ran Yun, Hye Ryun Kim, Sun Min Lim, Min-Soo Kim, Kwang-Won Hong, Sung-Moo Kim, Hwan Kim, Kyoung-Ho Pyo, Hye Ji Park, Joo Yeun Han, Hyun A Youn, Ki-Hwan Chang & Byoung Chul Cho. (2016) ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models. Lung Cancer 95, pages 57-64.
Crossref
Crossref
Bénédicte Rysman, François Mouawad, Abigaëlle Gros, Amélie Lansiaux, Dominique Chevalier & Samuel Meignan. (2016) Human epidermal growth factor receptor 3 in head and neck squamous cell carcinomas. Head & Neck 38:S1.
Crossref
Crossref
Ramaswamy Bhuvaneswari, Qin Feng Ng, Patricia S.P Thong & Khee-Chee Soo. (2015) Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model. Oncotarget 6:15, pages 13487-13505.
Crossref
Crossref
Qiao Li, Mark E.P. Prince & Jeffrey S. Moyer. (2015) Immunotherapy for head and neck squamous cell carcinoma. Oral Oncology 51:4, pages 299-304.
Crossref
Crossref
Yanyang Liu, Zhixi Li, Lu Wu, Zi Wang, Xia Wang, Yang Yu, Qian Zhao & Feng Luo. (2014) MiRNA-125a-5p: a regulator and predictor of gefitinib’s effect on nasopharyngeal carcinoma. Cancer Cell International 14:1.
Crossref
Crossref
Tania Crombet Ramos. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
1679
1694
.
LU WU, MEI LI, DINGYI LIU, MING JIANG, YANYANG LIU, ZHIXI LI, XIA WANG, YANG YU & FENG LUO. (2014) Treatment of nasopharyngeal carcinoma with pulmonary tuberculosis and gout: A case report. Oncology Letters 8:2, pages 753-757.
Crossref
Crossref
Ricardo CabanasGiselle SaurezJose AlertAdnolys ReyesJose ValdesMaria Caridad GonzalezJorge Luis PedrayesLuis ValleMariela InfanteMelba AvilaRaisa HerreraErnesto HechavarriaMarta RiosAymara FernándezPatricia Lorenzo LuacesTania Crombet Ramos. (2014) Prolonged Use of Nimotuzumab in Children with Central Nervous System Tumors: Safety and Feasibility. Cancer Biotherapy and Radiopharmaceuticals 29:4, pages 173-178.
Crossref
Crossref
B.K.M. Reddy, V. Lokesh, M.S. Vidyasagar, K. Shenoy, K.G. Babu, A. Shenoy, T. Naveen, Bindhu Joseph, R. Bonanthaya, Nanjundappa, P.P. Bapsy, Loknatha, Jayarama Shetty, Krishna Prasad & C.R. Tanvir Pasha. (2014) Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: A randomized, open-label, phase IIb, 5-year study in Indian patients. Oral Oncology 50:5, pages 498-505.
Crossref
Crossref
Roger B. Cohen. (2014) Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC). Cancer Treatment Reviews 40:4, pages 567-577.
Crossref
Crossref
Isao Tamura, Aiko Kamada, Seiji Goda, Yoshihiro Yoshikawa, Eisuke Domae & Takashi Ikeo. (2014) Effects of 4-(3-Chloro-Benzyl)-6,7-Dimethoxy-Quinazoline on Kinetics of P120-Catenin and Periplakin in Human Buccal Mucosa Squamous Carcinoma Cell Line. Open Journal of Stomatology 04:05, pages 249-257.
Crossref
Crossref
Hai-Tao Men, Hong-Feng Gou, Meng Qiu, Jian-Ping He, Ke Cheng, Ye Chen, Jun Ge & Ji-Yan Liu. (2014) A case of penile squamous cell carcinoma treated with a combination of antiepidermal growth factor receptor antibody and chemotherapy. Anti-Cancer Drugs 25:1, pages 123-125.
Crossref
Crossref
Neil Gildener-Leapman, Robert L. Ferris & Julie E. Bauman. (2013) Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncology 49:12, pages 1089-1096.
Crossref
Crossref
Wataru Okamoto, Takayuki Yoshino, Toshiaki Takahashi, Isamu Okamoto, Shinya Ueda, Asuka Tsuya, Narikazu Boku, Kazuto Nishio, Masahiro Fukuoka, Nobuyuki Yamamoto & Kazuhiko Nakagawa. (2013) A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 72:5, pages 1063-1071.
Crossref
Crossref
Yuan-yuan Qu, Song-liu Hu, Xiang-ying Xu, Rui-zhi Wang, Hong-yang Yu, Jian-yu Xu, Lin Chen & Guang-lu Dong. (2013) Nimotuzumab Enhances the Radiosensitivity of Cancer Cells In Vitro by Inhibiting Radiation-Induced DNA Damage Repair. PLoS ONE 8:8, pages e70727.
Crossref
Crossref
Hong-Feng Gou, Xiang Li, Meng Qiu, Ke Cheng, Long-Hao Li, Hang Dong, Ye Chen, Yuan Tang, Feng Gao, Feng Zhao, Hai-Tao Men, Jun Ge, Jing-Mei Su, Feng Xu, Feng Bi, Jian-Jun Gao & Ji-Yan Liu. (2013) Epidermal Growth Factor Receptor (EGFR)-RAS Signaling Pathway in Penile Squamous Cell Carcinoma. PLoS ONE 8:4, pages e62175.
Crossref
Crossref
Roshan James, Siddharth Vishwakarma, Indira V. Chivukula, Chetana Basavaraj, Ramakrishnan Melarkode, Enrique Montero & Pradip Nair. (2012)
EGFR
targeting monoclonal antibody combines with an
mTOR
inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs
. Cancer Medicine 1:2, pages 114-127.
Crossref
Crossref
Kelsey J. Rosbach, Michelle D. Williams, Ann M. Gillenwater & Rebecca R. Richards-Kortum. (2012) Optical Molecular Imaging of Multiple Biomarkers of Epithelial Neoplasia: Epidermal Growth Factor Receptor Expression and Metabolic Activity in Oral Mucosa. Translational Oncology 5:3, pages 160-171.
Crossref
Crossref
Hua-qing Wang, Yangang Ren, Zheng-zi Qian, Kai Fu, Hui-lai Zhang, Wei Li, Yun Hou, Shi-yong Zhou, Xi-shan Hao & Cong-hua Xie. (2012) Nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer. Thoracic Cancer 3:1, pages 72-78.
Crossref
Crossref
Jeffery S. Russell & A. Dimitrios Colevas. (2012) The Use of Epidermal Growth Factor Receptor Monoclonal Antibodies in Squamous Cell Carcinoma of the Head and Neck. Chemotherapy Research and Practice 2012, pages 1-13.
Crossref
Crossref
Keith D. Hunter & Robert Bolt. 2012. Biotargets of Cancer in Current Clinical Practice. Biotargets of Cancer in Current Clinical Practice
19
59
.
Ranee Mehra, Ilya G. Serebriiskii, Roland L. DunbrackJr.Jr., Matthew K. Robinson, Barbara Burtness & Erica A. Golemis. (2011) Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug Resistance Updates 14:6, pages 260-279.
Crossref
Crossref
Rolando Perez, Ernesto Moreno, Greta Garrido & Tania Crombet. (2011) EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab’s Clinical Effects. Cancers 3:2, pages 2014-2031.
Crossref
Crossref
Agustin Lage & Tania Crombet. (2011) Control of Advanced Cancer: The Road to Chronicity. International Journal of Environmental Research and Public Health 8:3, pages 683-697.
Crossref
Crossref